Table 4.

Recommendations for treatment duration

	Recommendation(s)
Initial treatment	Treatment should be continued for at least 4 months in order to obtain an initial response
Patients who
Have a complete hematological response	Continue lenalidomide therapy for as long as it continues to be well tolerated to avoid relapse (both erythroid and cytogenetic)
Have a partial response	Continue lenalidomide therapy, and consider an escalation of the lenalidomide dose to a maximum of 10 mg per day, if tolerable
Discontinue treatment because of adverse events	Patients should not begin another therapy immediately; it is recommended to wait 8–12 weeks to determine whether the response continues